Effects of Pitavastatin (LIVALO Tablet) on the Estimated Glomerular Filtration Rate (eGFR) in Hypercholesterolemic Patients with Chronic Kidney Disease

Kimura, Kenjiro; Shimano, Hitoshi; Yokote, Koutaro; Urashima, Mitsuyoshi; Teramoto, Tamio

doi:10.5551/jat.3764

Cited by 62 publications

(41 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the decline in GFR in the patients treated with pitavastatin tended to be steeper than that noted in the patients treated with pravastatin 9) . Finally, several reports have shown improvements in the kidney function with statin therapy in type 2 diabetic patients, unlike the present study 10,11,[33][34][35] . However, studies reporting improvements in the GFR with statin therapy involved post hoc sub-analyses of clinical trials designed to assess non-renal outcomes [33][34][35] .…”

Section: Discussioncontrasting

confidence: 53%

“…Finally, several reports have shown improvements in the kidney function with statin therapy in type 2 diabetic patients, unlike the present study 10,11,[33][34][35] . However, studies reporting improvements in the GFR with statin therapy involved post hoc sub-analyses of clinical trials designed to assess non-renal outcomes [33][34][35] . In addition, the follow-up duration in certain studies was inadequate to evaluate changes in the kidney function 10,11) .…”

Section: Discussioncontrasting

confidence: 53%

See 1 more Smart Citation

Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

Hanai

Babazono

Takemura

et al. 2015

JAT

View full text Add to dashboard Cite

Aim:Whether there are differences among statins in their effect on the kidney function in diabetic patients remains controversial. In this report, we aimed to examine the comparative effects of statins on the kidney function in a long-term follow-up study. Methods: This was a single-center longitudinal observational historical cohort study. We enrolled 326 Japanese adult ambulatory patients with type 2 diabetes who were newly prescribed one of four statins (pravastatin, rosuvastatin, atorvastatin and pitavastatin) and who had an estimated glomerular filtration rate (

show abstract

Section: Discussioncontrasting

confidence: 53%

Section: Discussioncontrasting

confidence: 53%

Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

Hanai

Babazono

Takemura

et al. 2015

JAT

View full text Add to dashboard Cite

show abstract

“…However, in our study, the pitavastatin group failed to demonstrate this effect. The actual reasons are unknown, but Kimura et al 21) revealed that an increase in eGFR in patients with diabetes/hypertension was less than that in patients without diabetes/hypertension, and similar results were obtained in patients with/without proteinuria. In addition, Kimura et al 21) have also pointed out that the amount change of HDL-C was a significant factor influencing changes in eGFR.…”

Section: Safetysupporting

confidence: 54%

“…Also, our prior report on the effects of lipid lowering with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy documented that rosuvastatin significantly decreased the levels of an oxidative stress marker, urinary 8-hydroxydeoxyguanosine 17,18) . Several preceding studies suggested that pitavastatin also has the effect to improve renal functions [19][20][21] . However, in our study, the pitavastatin group failed to demonstrate this effect.…”

Section: Safetymentioning

confidence: 99%

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease

Abe

Maruyama

et al. 2015

JAT

View full text Add to dashboard Cite

“…A meta-analysis 78) supports the notion that statins protect against the decline of renal function. Increased eGFR was also reported for Japanese patients with hypercholesterolemia 69,82) .…”

Section: Possible Reno-protective Effects Of Lipid-lowering Treatmentmentioning

confidence: 86%

Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis

Shoji

Abe

Matsuo³

et al. 2012

JAT

View full text Add to dashboard Cite

Patients with chronic kidney disease (CKD) are at an increased risk not only for end-stage kidney disease (ESKD) but also for cardiovascular disease (CVD). In this review article, we summarize the current evidence of CKD as a high-risk condition for CVD based on reports from Japan and other countries to draw attention to the close clinical association between CKD and CVD. Several epidemiologic studies have shown that the presence of CKD and reduced renal function are independent predictors of CVD also in Japan. According to a post-hoc analysis of CASE-J, the power of CKD as a predictor of CVD is as strong as diabetes mellitus and a previous history of ischemic heart disease. CKD worsens classical risk factors including hypertension and dyslipidemia, and dyslipidemia is associated with increased thickness and stiffness of large arteries independent of major confounders. A post-hoc analysis of MEGA indicates that lipid-lowering therapy with statins reduces the risk of CVD, and that it appears to be more efficacious in patients with than without CKD. These reports from Japan and other countries suggest that CKD should be regarded as a high-risk condition comparable to diabetes mellitus, and that strict control of dyslipidemia would be beneficial in preventing CVD, at least early stages of CKD.

show abstract

Effects of Pitavastatin (LIVALO Tablet) on the Estimated Glomerular Filtration Rate (eGFR) in Hypercholesterolemic Patients with Chronic Kidney Disease

Cited by 62 publications

References 23 publications

Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

Comparative Effects of Statins on the Kidney Function in Patients with Type 2 Diabetes

A Trial of Pitavastatin Versus Rosuvastatin for Dyslipidemia in Chronic Kidney Disease

Chronic Kidney Disease, Dyslipidemia, and Atherosclerosis

Contact Info

Product

Resources

About